摘要
程序性死亡受体-1(programmed death-1,PD-1)及配体PD-L1为CD28/B7免疫球蛋白超家族负性协同刺激分子成员,在许多肿瘤细胞及其相关细胞表面高表达。近年来免疫治疗成为肿瘤治疗的新热点,其中PD-1及配体PD-L1为靶点的免疫抑制药物在各类肿瘤临床试验中显示出了良好的疗效和安全性。本文将对近年来其在白血病、淋巴瘤等血液系统疾病治疗中的研究现状作一综述,以期为血液系统疾病的治疗提供新的方法。
Programmed death - 1 （ PD - 1 ） and its ligand PD - L1 are the members of inhibitory costimulatory mole- cules, belonging to the CD28/B7 immunoglobulin superfamily, and expressing high in a variety of tumor cells and their associated cells surface. Currently, cancer immunotherapy has become a new research hotspot, and PD - 1/PD - L1 in- hibitors could improve effects and be well - tolerated. This article will reviewed, the role of PD - 1/PD - L1 in leuke- mia,lymphoma and so on, in order to provide a new way to the treatment of hematolozical diseases.
出处
《现代肿瘤医学》
CAS
2017年第21期3531-3534,共4页
Journal of Modern Oncology
基金
国家自然科学基金(编号:81660417)
云南省教育厅科学研究基金重点项目(编号:2014Z056)
云南省应用基础研究计划项目(昆医联合专项)(编号:2014FB063,2014FB066)
